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LETTERS TO THE EDITOR 
Coronary Flow Reserve Assessment by 
Dobutamine Transesophageal 
Doppler Echocardiography 
We enjoyed the study by Stoddard et al. (1)* on coronary, flow reserve 
assessment by dobutamine transesophageal echocardiography. This 
important study demonstrated that dobutamine-induced coronary flow 
reserve was more sensitive than two-dimensional echocardiographic 
wall motion abnormalities for identifying intermediately severe left 
anterior descending coronary artery stenoses. 
However, we are concerned with two issues that were not 
addressed: 1) Coronary flow velocity measurements made proximal 
to the location of the stenosis may significantly influence the 
interpretation of the results. In regions proximal to stenoses in 
branching arterial systems, coronary flow may be higher than 
post-stenotic flow and flow reserve (2-4). Post-stenotic flow reserve 
would be a more precise index of the flow response and correlation 
with wall motion abnormalities. Preliminary data on proximally 
measured coronary flow during dobutamine infusion antedating 
post-stenotic measurement capability in patients from our labora- 
tory had demonstrated surprisingly similar results (5). 2) Although 
it is gratifying to see that there is a relation between coronary flow 
reserve and the severity of angiographic stenoses, the large overlap 
of the data for groups A and B suggests there is considerable 
imprecision when attempting to differentiate between patients with 
<70% stenoses, as has been previously demonstrated by direct 
post-stenotic flow measurements (2). Identification of a transle- 
sional jet velocity for use with reference vessel cross-sectional rea 
would more precisely assign stenosis severity, as previously de- 
scribed by Johnson et al. (6). 
The physiologic assessment of indeterminate coronary, stenoses in 
the cardiac catheterization laboratory is an important issue. However, 
because of the aforementioned limitations, transesophageal echocar- 
diographic oronary flow reserve should be validated against directly 
measured flow as opposed to angiography to demonstrate superiority 
to two-dimensional wall motion analysis for intermediately severe 
lesions. 
MORTON J. KERN, MD, FACC 
THOMAS J. DONOHUE,  MD, FACC 
Cardiology Division 
Saint Louis" University Health Sciences Center 
Saint Louis', Missouri 63110 
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Carvedilol Therapy in Heart Failure---I 
The report by Olsen et aL (1) provides interesting and intriguing data 
on the potential therapeutic use of carvedilol in the management of 
heart failure in patients with impaired left ventricular systolic function. 
The baseline characteristics indicate that there were twice as many 
patients in functional class III in the carvedilol group (n = 20) as in the 
placebo group (n = 10). Moreover, norepinephrine levels were 
significantly higher in the carvedilol group. This disparity raises the 
possibility that the marked improvement in the carvedilol group partly 
reflects the higher prevalence of more advanced heart failure in that 
group. Such patients may respond particularly well to intervention. In 
the CONSENSUS trial (2), enalapril primarily reduced the mortality 
rate in patients who had the greatest neurohormonal activation at 
baseline. Similarly, in the V-HeFF II study (3), reduction in mortality 
with enalapril compared with the combination of hydralazine and 
isosorbide dinitrate was greatest in patients with the greatest activation 
of neurohormones at baseline. Thus, the difference in baseline char- 
acteristics has the potential to exaggerate the beneficial effects of 
carvedilol. 
JALAL K. GHALI, MD, FACC 
l.ouisiana State University Medical Center 
150l Kings Highway 
Shreveport, Louisiana 71130 
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Carvedilol Therapy in Heart Failure--ll 
I read with much interest he article by Olsen et al. (1) describing 
the effects of a beta-adrenergic blocking agent (carvedilol) on 
symptoms and clinical variables in patients with heart failure. Heart 
failure is a condition with enormous repercussions, and information 
regarding its treatment is anticipated. Treatment with beta-blockers 
seems to be gaining a role in the management of heart failure. 
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